Bio
Wendy Clemens is Vice President of Early Development Oncology, Bristol Myers Squibb, leading a team of scientists that develop novel oncology therapeutics from pre-clinical stage through proof-of-concept. These innovative therapies are designed to activate the immune system to kill tumor cells in patients with advanced malignancies with high unmet medical need. Overall, Wendy has over 20 years of experience in the pharmaceutical industry where she has served in various scientific roles focused on immunology, infectious disease and oncology at several pharmaceutical companies including Bristol Myers Squibb, Tmunity, MedImmune/Astra Zeneca and Merck. Wendy received her BS from Penn State University in Animal Bioscience, her MS from University of Missouri in Veterinary Immunology and her PhD from the Department of Physiology at Penn State University. Her Post-Doctoral Research Fellowship was conducted at the Food and Drug Administration in Bethesda, Maryland. Wendy lives in Bucks County, Pennsylvania with her husband, two step-daughters and two dogs.
Education
- BS, Animal Bioscience, Penn State, 1996
- MS, Veterinary Immunology, Univ. of Missouri, 1998
- PhD, Physiology/Immunology, Penn State, 2005
Research Interests
Development of oncology therapeutics that target the tumor microenvironment and stimulate the anti-tumor immune response. Responsible for a portfolio of therapies that are in pre-clinical stage through FIH (first in human) and POC (proof of concept) clinical trials.
Publications
1. Immune Monitoring After NKTR-214 Plus Nivolumab (PIVOT-02) in Previously Untreated Patients With Metastatic Stage IV Melanoma. A. Diab, S. Tykodi, B. Curti, D. Cho, M. Wong, I. Puzanov, K. Lewis, M. Maio, G. A. Daniels, A. Spira, M. Tagliaferri, A. Hannah, W. Clemens, M. Imperiale, C. Bernatchez, C. Haymaker, S. E. Bentebibel, J. Zalevsky, U. Hoch, C. Fanton, A. Rizwan, S. Aung, F. Cattaruzza, E. Iaccucci, D. Sawka, M. Bilen, P. Lorigan, G. Grignani, J. Larkin, S. Jang, E. K. Warzocha, H. Kluger, M. Sznol and M. Hurwitz. SITC 2018.
2. NKTR-214 (CD-122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. A. Diab, M. Hurwitz, D. Cho, V. Papadimitrakopoulou, B. Curti, S. Tykodi, I. Puzanov, N. K. Ibrahim, S. M. Tolaney, D. Tripathy, J. Gao, A. O. Siefker-Radtke, W. Clemens, M. Tagliaferri, S. N. Gettinger, H. Kluger, J. M. G. Larkin, G. Grignani, M. Sznol and N. Tannir. ASCO 2018.
3. PIVOT-02: Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/2 study of CD-122 biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic melanoma, RCC and NSCLC. A. Diab, N. Tannir, D. Cho, V. Papadimitrakopoulou, C. Bernatchez, C. Haymaker, B. Curti, M. Wong, S. Tykodi, I. Puzanov, I. Smallberg, I. Gergel, M. Tagliaferri, U. Hoch, W. Clemens, M. Imperiale, J. Zalevsky, S. N. Gettinger, H. Kluger, M. Hurwitz, P. Hwu and M. Sznol. SITC 2017.
4. Phase 1b Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination With Lenalidomide Plus Low-Dose Dexamethasone, or With Bortezomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma. Ghobrial I, Perez R, Baz R, Richardson P, Anderson K, Sabbatini P, DiLea C, Cardarelli P, Wade M, Xing G, Clemens-Trigona W, Gutierrez A, Cohen L, Becker P. ASH 2014.
5. Development of a highly sensitive liquid chromatography/tandem mass spectrometry method to quantify total and free levels of a target protein, interferon-gamma-inducible protein-10, at picomolar levels in human serum. Zhang H, Xiao Q, Xin B, Trigona W, Tymiak AA, Dongre AR, Olah TV. Rapid Comm Mass Spec. 2014 Jul 15;28(13):1535-43.
6. Anti-IL-6 Antibody Clazakizumab is More Potent than Tocilizumab in Blocking In Vitro and Ex Vivo IL-6-induced Functions. Zhao Q., Pang J., Shuster D., Hung C., Baglino S., Dodge R., Sun H., Trigona W. and L. Salter-Cid. Poster Presentation. ACR 2013.
7. Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus.. Yao Y., Higgs B.W., Morehouse C., de los Reyes M., Brohawn P., Trigona W., White W., Zhang J., White B., Coyle A., Kiener P.A., and B. Jallal. Human Genomics and Proteomics. 2009 Nov 17;2009.
8. The Pro-inflammatory Cytokines IL-17A, IL-17F and TNF-alpha significantly Contribute to the Psoriatic Gene Signature in the Skin. Trigona, W.L. Oral Presentation. Federation of Clinical Immunology Societies (FOCiS) 2009. San Francisco, CA.
9. Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models. Mulgrew K., Stewart D., Sabol D., Trigona W.L., Ryan P., et al. Poster Presentation. AACR 2008, San Diego, CA.
10. Selenium inhibits 15- hydroperoxyoctadecadienoic acid-induced intracellular adhesion molecule expression in aortic endothelial cells. Sordillo L.M., Streicher K.L., Mullarky I.K., Gandy J.C., Trigona W.L., Corl C.M. Free Radic Biol Med. 44(1):34-43. January 2008.
11. Could heme-oxygenase-1 have a role in modulating the recipient immune response to embryonic stem cells? Trigona W.L., Porter C.M., Horvath-Arcidiacono J.A., Majumdar A.S., Bloom E.T. Antioxididants and Redox Signaling. 9(6):751-6. June 2007.
12. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. Fu T.M., Dubey S.A., Mehrotra D.V., Freed D.C., Trigona W.L., Adams-Muhler L., Clair J.H., Evans T.G., Steigbigel R., Jacobson J.M., Goepfert P.A., Mulligan M.J., Kalams S.A., Rinaldo C., Zhu L., Cox K.S., Guan L., Long R., Persaud N., Caulfield M.J., Sadoff J.C., Emini E.A., Thaler S., Shiver J.W. AIDS Res Hum Retroviruses. 23(1):67-76. January 2007.
13. Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells. Trigona W.L., Mullarky I.K., Cao Y., Sordillo L.M. Biochemical Journal. 394(Pt 1):207-16. February 2006.
14. Intracellular staining for HIV-specific IFN- gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses. Trigona W.L., Clair J.H., Persaud N., Punt K., Dubey S., Tussey L., Fu T.M. and J. Shiver. Journal of Interferon and Cytokine Research. 23(7): 369-377. July 2003.
15. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus and replication-defective adenovirus vectors expressing a human immunodeficiency virus type I gag gene. Casimiro D.R., Chen L., Fu T.M., Evans, R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., Freed D.C., Wilson K., Dubey S., Zhu D.M., Nowrocki D., Mach., Troutman R., Isopi L., Williams D., Hurni W., Xu Z., Smith JG, wang S., Liu X., Guan L., Long R., Trigona W.L., Heideker G., Perry H., Persaud N., Toner T., Su Q., Liang X., Youil R., Chastain M., Bett A.J., Volkin D.B, Emini E.A. and J.W. Shiver. Journal of Virology. 77(11): 6305-6313. June 2003.
16. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. Zhang Z.Q., Fu T.M., Casimiro D.R., Davies M.E., Liang X., Schleif W.A., Handt L., Tussey L., Chen M., Tang A., Wilson K., Trigona W.L., Freed D.C., Tan C.Y., Horton M., Emini E.A. and J.W. Shiver. Journal of Virology. 76(24): 12845-12854. December 2002.
17. Replication-Incompetent Adenoviral Vaccine Vector Elicits Effective Anti-Immunodeficiency Virus Immunity. Shiver, J., Fu, T., Chen, L., Casimiro, D., Davies, M., Evans, R., Zhang, Z., Simon, A., Trigona, W.L., Dubey, S., Huang, L., Harris, V., Long, R., Liang, X., Handt, L., Schleif, W., Zhu, L., Freed, D., Persaud, N., Guan, L., Punt, K., Tang, A., Chen, M., Wilson, K., Collins, K., Heideker, G., Perry, H., Joyce, J., Grimm, K., Cook, J., Keller, P., Kresock, D., Mach, H., Troutman, R., Isopi, L., Williams, D., Xu, Z., Bohannon, K., Volkin, D., Montefiori, D., Miura, A., Krivulka, G., Lifton, M., Kuroda, M., Schmitz, J., Letvin, N., Caulfield, M., Bett, A., Youil, R., Kaslow, D. and E. Emini. Nature. 415: 331-335. January 2002.
18. An Enhanced and Scalable Process for the Purification of SIV gag-Specific Tetramer. Grimm, K., Trigona, W.L., Heideker, G., Joyce, J., Fu, T., Shiver, J., Keller, P. and J. Cook. Protein Expression and Purification. 23: 270-281. November 2001.
19. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. Maekker, H., Dunn, H., Suni, M., Khatamzas, E., Pitcher, C., Bunde, T., Persaud, N., Trigona, W.L., Fu, T., Sinclair, E., Bredt, B., McCune, J., Maino, V., Kern, F. and L. Picker. Journal of Immunological Methods. 255: 27-40. September 2001.
20. Evaluation of Cytotoxic T-Lymphocyte Responses in Human and Nonhuman Primate Subjects Infected with Human Immunodeficiency Virus Type 1 or Simian/Human Immunodeficiency Virus. Fu, T., Freed, D. C., Trigona, W.L., Guan, L., Zhu, L., Long, R., Dubey, S., Persaud, N., Manson, K. and J. Shiver. Journal of Virology. 75(1): 73-82. January 2001.
21. Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination. Barouch, D., Santra, S., Schmitz, J., Kuroda, M., Fu, T., Wagner, W., Bilska, G., Craiu, A., Zheng, X., Krivulka, G., Beaudry, K., Lifton, M., Nickerson, C., Trigona, W.L., Punt, K., Freed, D., Guan, L., Dubey, S., Casimiro, D., Simon, A., Davies, M., Chastain, M., Strom, T., Gelman, R., Montefiori, D., Lewis, M., Emini, E., Shiver, J. and N. Letvin. Science. 290: 486- 492. October 2000. 22. Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses cannot be predicted by MHC Class I Haplotype. Betts, M.R., Casazza, J.P., Patterson, B.A., Waldrop, S., Trigona, W.L., Fu, T., Kern, F., Picker, L. J. and R.A. Koup. Journal of Virology. 74: 9144-9151. October 2000.